Earnings Releases·Nov 5, 2026, 5:00 PM ET

NeOnc Technologies — Third Quarter 2026 Earnings Summary

Net loss narrowed to $4.4 million in Q3 2026 from $8.6 million in Q3 2025, while total operating expenses fell to $5.8 million from $6.9 million year-over-year; R&D expenses rose to $1.3 million compared to $0.7 million in the prior year period.
The NEO100 Phase 2a study met its primary endpoint with a 48.9% six-month progression-free survival rate versus a 20% benchmark, and the company closed a $15 million registered direct offering while redeeming all Series A Preferred Stock to eliminate dilution.
NEO212 is advancing toward Phase 2 development following FDA feedback on formulation changes, with Phase 1 data scheduled for presentation in November, alongside a non-binding MoU signed with the Department of Health – Abu Dhabi for clinical collaboration.
Management highlighted a strengthened balance sheet with cash and equivalents rising to $6.2 million as of September 30, 2026, though the company cautioned that substantial additional capital is required to fund operations and may not be available on acceptable terms.